Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioLineRx has announced that the first patient treated with BL-1040 was released from the Department of Cardiology at the University of Heidelberg in Germany, following treatment with no apparent adverse effects.
Subscribe to our email newsletter
This was the first patient in a Phase I/II clinical trial study that is designed to assess the safety and feasibility of BL-1040 in up to 30 patients at several sites in Germany, Belgium, and Israel. The company expects to complete the first part of the trial towards the end of this year. BL-1040 is being developed as a class III medical device utilizing FDA’s pre-marketing approval regulatory pathway approach.
Morris Laster, CEO of BioLineRx, said: “This is an important milestone in the development of BL-1040, BioLineRx’s innovative product candidate, which is the first treatment that attempts to treat damaged cardiac tissue resulting from an acute myocardial infarction (MI) and addresses a tremendous unmet medical need. We plan to closely monitor this and future BL-1040 patients for safety.”